MBX Biosciences names Steve Hoerter CEO and chairman, John Smither CFO

The leadership changes take effect immediately as MBX says it remains on track for three second-half 2026 milestones across hypoparathyroidism and obesity programs.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.